Pharmaceutical firm Bracco plans to establish imaging operations in the U.K. and Ireland by the end of this year, the Milan-based firm announced this month. The move allows Bracco to take over operations in these two countries currently managed by Merck
Pharmaceutical firm Bracco plans to establish imaging operations in the U.K. and Ireland by the end of this year, the Milan-based firm announced this month. The move allows Bracco to take over operations in these two countries currently managed by Merck Pharmaceuticals Imaging, a division of Merck of Germany. Merck Pharmaceuticals will continue to distribute Braccos contrast media products in the U.K. and Ireland until Braccos operations are in place. Bracco products distributed by Merck include x-ray contrast agents Niopam and Iomeron, as well as MRI agents ProHance and MultiHance.
The agreement is part of Braccos move to acquire Mercks 50% share in its imaging and pharmaceutical businesses, which was announced in January. Pending regulatory approval, Bracco will pay Merck $900 million over five years (SCAN 1/12/00).
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.